17,345 results match your criteria Journal of Nuclear Medicine[Journal]


A Quantitative Evaluation of Joint Activity and Attenuation Reconstruction in TOF-PET/MR Brain Imaging.

J Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

KU Leuven, Belgium.

Time of flight (TOF) positron emission tomography (PET) data provide an effective means for attenuation correction (AC) when no (or incomplete/inaccurate) attenuation information is available. Since magnetic resonance (MR) scanners provide little information on photon attenuation of different tissue types, AC in hybrid PET/MR scanners has always been challenging. In this contribution, we aim at validating the activity reconstructions of the maximum likelihood activity and attenuation reconstruction (MLAA) algorithm on a patient brain dataset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220871DOI Listing

New Developments in Imaging Cell-based Therapy.

J Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

King's College London, United Kingdom.

Cancer immunotherapy is now established as a central therapeutic pillar in hematologic oncology. Cell based therapies, with or without genetic modification ex vivo, have reached the clinic as standard of care in limited indications and remain the subject of intense pre-clinical and translational development. Expanding on this, related therapeutic approaches are in development for solid tumor and non-malignant indications, broadening the scope of this technology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.213348DOI Listing

Presynaptic striatal dopaminergic function in atypical parkinsonisms: A meta-analysis of imaging studies.

J Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

University of Turku.

Multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) have overlapping signs and symptoms with Parkinson's disease (PD), and these similarities complicate their clinical diagnostics. Although presynaptic dopaminergic brain imaging with PET and SPECT is clinically widely used for patients with suspected PD, the benefit of functional imaging in atypical parkinsonism syndromes remains unclear. We compared striatal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS and PD using combined quantitative data from all published studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.227140DOI Listing

A Prospective Study on F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.

J Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

BC Cancer, Canada.

F-DCFPyL, a prostate specific membrane antigen targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity and impact on patient management of F-DCFPyL in the settings of biochemical recurrence of prostate cancer. Subjects with prostate cancer and biochemical recurrence post radical prostatectomy/curative intent radiotherapy were included in this prospective study. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.119.226
Publisher Site
http://dx.doi.org/10.2967/jnumed.119.226381DOI Listing
April 2019
1 Read

Improving 68-Ga-PSMA PET/MR hybrid imaging of the prostate with un-renormalized absolute scatter correction.

J Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

University of Duisburg-Essen, Germany.

A limitation of using 68-gallium-labelled prostate-specific membrane antigen (68-Ga-PSMA) for detection and staging of prostate cancer is a frequently observed halo artifact around the urinary bladder caused by inaccurate scatter correction (SC) of positron emission tomography (PET) data. The aim of this study is to investigate the impact of un-renormalized absolute SC on 68-Ga-PSMA PET quantification in PET/magnetic resonance (MR) hybrid imaging of the prostate in 100 patients. The PET data of 100 patients were reconstructed twice using standard SC and improved un-renormalized SC. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.224
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.224139DOI Listing
April 2019
2 Reads

Training Requirements for Theranostics - a Unique Opportunity for Collaboration.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

University of Iowa, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.228940DOI Listing

Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

LYSA-IM, Hospital Henri Mondor, France.

Increased tumour burden is associated with inferior outcomes in many lymphoma subtypes. Surrogates of tumour burden that are easy to measure, such as the maximum tumour dimension of the 'bulkiest' lesion on CT have been used as prognostic indices for many years. Recently, the total metabolically (active) tumour volume (M(A)TV) and tumour lesion glycolysis (TLG) have emerged as promising and robust biomarkers of outcome in various lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.227249DOI Listing

Tumor imaging using radiolabelled matrix metalloproteinase-activated anthrax proteins.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

Department of Oncology, University of Oxford, United Kingdom.

Increased activity of matrix metalloproteinases (MMPs) is associated with worse prognosis in different cancer types. The protective antigen (PA-WT) of the binary anthrax lethal toxin was modified to form a pore in cell membranes only when cleaved by MMPs (PA-L1). Anthrax lethal factor (LF) is then able to translocate through these pores. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.226423DOI Listing

Early Detection of Multiorgan Light Chain (AL) Amyloidosis by Whole Body F-florbetapir PET/CT.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

Brigham and Women's Hospital, United States.

Immunoglobulin light chain amyloidosis (AL) affects multiple systemic organs. However, determination of the precise extent of organ involvement remains challenging. Targeted amyloid imaging with F-florbetapir PET/CT offers the potential to detect AL amyloid deposits in multiple organs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.221770DOI Listing
April 2019
3 Reads

A pilot study on hepatobiliary scintigraphy to monitor regional liver fucntion in yttrium-90 radioembolization.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

University Medical Center Utrecht, Netherlands.

Radioembolization is increasingly used as a bridge to resection (i.e. radiation lobectomy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.224394DOI Listing
April 2019
1 Read

Preclinical Characterization of Y-NM600 in a variety of murine and human cancer tumor models.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

University of Wisconsin - Madison, United States.

We characterize the in vivo biodistribution and tumor selectivity of Y-NM600, a theranostic alkylphosphocholine radiometal chelate with broad tumor selectivity, in a variety of preclinical cancer models. Mice bearing flank tumors (representative of lung, pancreatic, prostate, liver, skin, and lymphoid cancers) were injected intravenously (IV) with 9.25 MBq of Y-NM600 and imaged longitudinally over 4-5 days using microPET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.224808DOI Listing
April 2019
2 Reads

F-Fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

Emory University, United States.

We evaluated F-fluciclovine uptake parameters that correlate with true positivity for local recurrence in non-prostatectomy treated patients. Twenty-one patients (prostate-specific antigen 7.4±6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.227033DOI Listing
April 2019
3 Reads

FAPI-PET/CT: Mean intensity of tracer-uptake (SUV) in 28 different kinds of cancer.

J Nucl Med 2019 Apr 6. Epub 2019 Apr 6.

University Hospital Heidelberg, Germany.

The recent development of quinoline based positron-emission-tomography (PET)-tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer associated fibroblasts (CAFs) of several tumor entities. Here we quantify the tumor-uptake in FAPI-PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.227967DOI Listing
April 2019
1 Read

Update: Image Gently and Nuclear Medicine at 10 Years.

J Nucl Med 2019 Apr;60(4):7N-9N

Boston Children's Hospital/Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source

DOE Selects 4 Companies for Mo Production.

Authors:

J Nucl Med 2019 Apr;60(4):13N

View Article

Download full-text PDF

Source

Report from ABNM: Board of Directors Selection.

Authors:
Leonie Gordon

J Nucl Med 2019 Apr;60(4):10N

View Article

Download full-text PDF

Source

Erratum.

Authors:

J Nucl Med 2019 Apr;60(4):554

View Article

Download full-text PDF

Source

Erratum.

Authors:

J Nucl Med 2019 Apr;60(4):529

View Article

Download full-text PDF

Source

A Conversation Between Michael Phelps and Jason Lewis.

J Nucl Med 2019 Apr;60(4):439-442

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.119.228
Publisher Site
http://dx.doi.org/10.2967/jnumed.119.228296DOI Listing
April 2019
1 Read

Artificial Intelligence in Nuclear Cardiology.

J Nucl Med 2019 Mar 29. Epub 2019 Mar 29.

Cook County Health, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222356DOI Listing

Progressive tau accumulation in Alzheimer's disease: two-year follow-up study.

J Nucl Med 2019 Mar 29. Epub 2019 Mar 29.

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Korea, Republic of.

Tau positron emission tomography (PET) enabled in vivo visualization and quantitation of tau pathology in Alzheimer disease (AD). In cross-sectional tau PET studies, tau burden reflected disease severity and phenotypic variation. We investigated longitudinal change in cortical tau accumulation and its associations with cognitive decline in patients with Alzheimer disease (AD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.221697DOI Listing
March 2019
1 Read

rA1M is a potential kidney protector in Lu-octreotate treatment of neuroendocrine tumors.

J Nucl Med 2019 Mar 29. Epub 2019 Mar 29.

Institution of Clinical Sciences, Sweden.

Treatment of neuroendocrine tumors (NETs) with Lu-octreotate results in prolonged survival and improved quality of life for the patient. However, the treatment is today limited by side effects on kidney and bone marrow and complete tumor remission is rarely seen. A possible way to minimize dose-limiting toxicity and to optimize this treatment method is to use radio-protectors in conjunction with radiotherapy. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.225
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.225243DOI Listing
March 2019
5 Reads

Prediction of time to hormonal treatment failure in metastatic castrate-sensitive prostate cancer with F-FDG PET/CT.

J Nucl Med 2019 Mar 29. Epub 2019 Mar 29.

University of Southern California, United States.

The aim of this prospective investigation was to assess the association of F-FDG PET/CT with time to hormonal treatment failure (THTF) in men with metastatic castrate-sensitive prostate cancer (mCSPC). 76 men with mCSPC recruited from 2005-2011 underwent F-FDG PET/CT and were followed prospectively for THTF, defined as treatment change to chemotherapy or death. Patients who had not switched to chemotherapy were censored at the last follow-up date (median of 36 months, range 12-108 months). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223263DOI Listing

F-FDG PET/MRI for therapy response assessment of isolated limp perfusion in patients with soft-tissue sarcomas.

J Nucl Med 2019 Mar 29. Epub 2019 Mar 29.

University Hospital Essen, Germany.

To assess the diagnostic potential of simultaneously acquired F-FDG PET- and MR datasets for therapy response assessment of isolated limp perfusion (ILP) in patients with soft-tissue sarcomas (STS). A total of 45 patients with histopathologically verified STS were prospectively enrolled for an integrated F-FDG PET/MR examination before and after ILP. Therapy response was assessed based on different MR- and PET-derived morphological (RECIST, MR-adapted Choi criteria) and metabolic (PERCIST) criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.226761DOI Listing

Preclinical pharmacokinetics and dosimetry studies of [I/I]-CLR1404 for treatment of pediatric solid tumors in murine xenograft models.

J Nucl Med 2019 Mar 29. Epub 2019 Mar 29.

University of Wisconsin-Madison, United States.

Pediatric cancer is the second leading cause of death for children between the ages of 5-14. For children diagnosed with metastatic or recurrent solid tumors, where the utility of external-beam radiotherapy is limited, the prognosis is particularly poor. The availability of tumor-targeting radiopharmaceuticals for molecular radiotherapy (MRT) has demonstrated improved outcomes in these patient populations, but options are nonexistent or limited for most pediatric solid tumors. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.225
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.225409DOI Listing
March 2019
6 Reads

The impact of emerging bioconjugation chemistries on radiopharmaceuticals.

J Nucl Med 2019 Mar 22. Epub 2019 Mar 22.

University of Zurich, Switzerland.

The use of radiolabeled antibodies, immunoglobulin fragments and other proteins are an increasingly important sector of research for diagnostic imaging and targeted radiotherapy in Nuclear Medicine. As with all radiopharmaceuticals, efficient radiochemistry is a prerequisite to clinical translation. For proteins, variations in the primary amino acid sequence, the secondary structures and tertiary folds, as well as differences in size, charge, polarity, lipophilicity, and the presence of post-translational modifications, add complexity to the system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220806DOI Listing

Bone marrow absorbed doses and correlations with hematological response during Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases.

J Nucl Med 2019 Mar 22. Epub 2019 Mar 22.

Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg, Sweden.

This study aimed to compare different image-based methods for bone marrow dosimetry and study the dose-response relationship during treatment with Lu-DOTATATE in patients with and without skeletal metastases. Methods. This study included 46 patients with advanced neuroendocrine tumors treated with at least two fractions of Lu-DOTATATE at Sahlgrenska University Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.225235DOI Listing

Impact of F-PSMA-1007 uptake in prostate cancer using different peptide concentrations: preclinical PET/CT study in mice.

J Nucl Med 2019 Mar 22. Epub 2019 Mar 22.

Osaka University Graduate School of Medicine, Japan.

PET radioligands with low molar activity (MA) may underestimate the quantity of the target of interest because of competitive binding of the target with unlabeled ligand. The aim of this study was to evaluate the change in the whole-body distribution of F-PSMA-1007 targeting prostate specific membrane antigen (PSMA), using solutions with different peptide concentrations. Mouse xenograft models of LNCaP (PSMA-positive prostate cancer) (n = 18) were prepared and divided into three groups according to the peptide concentration injected: high MA group (1,013 ± 146 GBq/µmol; n = 6), medium MA group (100. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223479DOI Listing
March 2019
2 Reads

The contribution of multiparametric pelvic & whole body MR to interpretation of F-fluoromethylcholine or Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure following radical prostatectomy.

J Nucl Med 2019 Mar 22. Epub 2019 Mar 22.

St Vincent's Hopsital, Australia.

To assess whether the addition of data from multiparametric pelvic (mpMR) and whole body MR (wbMR) to the interpretation of F-fluoromethylcholine (FCH) or Ga-HBED-CC PSMA-11 (PSMA) PET/CT (=PET) improves the detection of local tumor recurrence, or nodal and distant metastases in patients following radical prostatectomy with biochemical failure. The current analysis was performed as part of a prospective, multicenter trial on FCH / PSMA PET, mpMR and wbMR. Eligible men had elevated PSA (>0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.225185DOI Listing

A dual-modality linker enables site-specific conjugation of antibody fragments for F-immunoPET and fluorescence imaging.

J Nucl Med 2019 Mar 15. Epub 2019 Mar 15.

Beckman Research Institute of the City of Hope, United States.

Antibody-based dual-modality (PET/fluorescence) imaging enables both pre-surgery antigen-specific immunoPET for non-invasive whole-body evaluation and intra-operative fluorescence for visualization of superficial tissue layers for image guided surgery. We developed a universal dual-modality linker (DML) that facilitates 1) site-specific conjugation to a cysteine residue bearing antibody fragment; 2) introduction of a commercially available fluorescent dye (via amine-reactive prosthetic group); 3) rapid and efficient radiolabeling via click chemistry with F-labeled trans-cyclooctene (F-TCO). To generate a dual-modality antibody fragment based imaging agent, the DML was labeled with the far-red dye sulfo-Cy5 (sCy5), site-specifically conjugated to the C-terminal cysteine of the anti-prostate stem cell antigen (PSCA) cys-diabody A2 (A2cDb), and subsequently radiolabeled by click chemistry with F-TCO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223560DOI Listing

Effect of off-target binding on F-Flortaucipir variability in healthy controls across the lifespan.

J Nucl Med 2019 Mar 15. Epub 2019 Mar 15.

Lawrence Berkeley National Laboratory, United States.

Measuring early tau accumulation is important in studying aging and Alzheimer's disease (AD) and is only as accurate as the signal to noise ratio of the tracer. Along with aggregated tau in the form of neurofibrillary tangles, F-Flortaucipir (F-FTP) has been reported to bind to neuromelanin, monoamine oxidase, calcification, iron, lepto-meningeal melanocytes, and microhemorrages. Although F-FTP successfully differentiates healthy controls (HC) from subjects with AD, variability exists in the cortical signal in amyloid-β negative (Aβ-) HCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.224113DOI Listing
March 2019
2 Reads

Dual-time-point F-fluorocholine PET/CT in Parathyroid Imaging.

J Nucl Med 2019 Mar 15. Epub 2019 Mar 15.

Noordwest Ziekenhuisgroep, Netherlands.

F-fluorocholine (FCH) PET/CT is a promising and increasingly used scan technique in preoperative imaging of parathyroid adenoma. Several acquisition methods have been evaluated in literature but the optimal image acquisition time point after administration of the tracer is still under debate. Patients with hyperparathyroidism, who received a dual-time-point FCH PET/CT (image acquisition 5 min and 60 min post injection) with histologically proven pathological parathyroid glands were retrospectively included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.225599DOI Listing
March 2019
1 Read

Trends and challenges for the clinical adoption of fluorescence-guided surgery.

J Nucl Med 2019 Mar 15. Epub 2019 Mar 15.

Barrow Neurological Institute, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.226795DOI Listing

Accuracy of F-FDG PET/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer.

J Nucl Med 2019 Mar 15. Epub 2019 Mar 15.

Department of Radiology and Nuclear Medicine, Erasmus MC - University Medical Center Rotterdam, Netherlands.

To prospectively investigate optimal evaluation of qualitative and quantitative F-FDG PET/CT in response evaluations 12-14 weeks after neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer patients. This is a side-study of the prospective diagnostic preSANO trial. F-FDG PET/CT scans at baseline and at 12-14 weeks after nCRT were qualitatively assessed for presence of tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.224196DOI Listing

An International Survey of PET/CT Clinical Reporting.

J Nucl Med 2019 04 15;60(4):478-479. Epub 2019 Mar 15.

Department of Diagnostic Imaging, Warren Alpert Medical School of Brown University, Providence, Rhode Island.

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.223
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.223073DOI Listing
April 2019
3 Reads

F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival to Preoperative Radiochemotherapy with Bevacizumab in High Risk Locally Advanced Rectal Cancer.

J Nucl Med 2019 Mar 15. Epub 2019 Mar 15.

INT Fondazione G. Pascale, Italy.

There is an unmet need for predictive biomarkers of the clinical benefit of anti-angiogenic drugs.The aim of the present study was to prospectively evaluate the value of FDG-PET/CT performed during and after preoperative radiochemotherapy (CRT) with bevacizumab for the prediction of complete pathologic tumor regression and survival in magnetic resonance imaging (MRI)-defined high-risk locally advanced rectal cancer (LARC) patients Sixty-one patients treated in a non-randomized phase II study (BRANCH) with concomitant or sequential (4 days before CRT) administration of bevacizumab with preoperative CRT were included. F-FDG PET/CT was performed at baseline, 11 days after the beginning of the CRT (early) and before surgery (late). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222604DOI Listing
March 2019
1 Read
6.160 Impact Factor

IMAGING THE ENZYME 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 WITH POSITRON EMISSION TOMOGRAPHY: EVALUATION OF THE NOVEL RADIOTRACER C-AS2471907 IN HUMAN BRAIN.

J Nucl Med 2019 Mar 15. Epub 2019 Mar 15.

Yale University, United States.

The 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme converts cortisone to cortisol, and participates in the regulation of glucocorticoid levels in tissues. 11β-HSD1 is expressed in the liver, kidney, adipose, placenta and brain. 11β-HSD1 is a target for treatment of depression, anxiety, PTSD and also against age-related cognitive function and memory loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.219766DOI Listing

Multispectral optoacoustic tomography of benign and malignant thyroid disorders - a pilot study.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

Department of Nuclear Medicine, University Hospital Münster, Germany, Germany.

This study aims at evaluating hybrid multispectral optoacoustic tomography (MSOT)/ultrasound for imaging of thyroid disorders, including Graves' disease and thyroid nodules. The functional biomarkers and tissue parameters deoxygenated (HbR), oxygenated (HbO2) and total hemoglobin (HbT), saturation of hemoglobin (sO2), fat and water content were analyzed in thyroid lobes affected by Graves' disease ( = 6), thyroid lobes with healthy thyroid tissue ( = 8), benign ( = 13) and malignant ( = 3) thyroid nodules. In Graves' disease, significantly higher values for HbR (3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222174DOI Listing
March 2019
1 Read

In-pentetreotide scintigraphy vs. Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

National Institutes of Health, United States.

Eligibility for somatostatin receptor (SSTR) radionuclide therapy uses the qualitative Krenning Score based on In-pentetreotide planar scintigraphy as was performed in the NETTER-1 trial. The purpose of this study was to determine the effect of using SSTR-PET-based Krenning Score in comparison to In-pentetreotide. This was a post-hoc head-to-head comparison of Ga-DOTATATE-based and In-pentetreotide-based Krenning scores in 150 patients included in a prospective phase 2 study (NCT01967537). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223016DOI Listing
March 2019
1 Read

Dynamic C-PiB PET shows cerebrospinal fluid flow alterations in Alzheimer's disease and multiple sclerosis.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

King's College London, United Kingdom.

Cerebrospinal fluid (CSF) plays an important role in the clearance of solutes and maintenance of brain homeostasis. C-PiB PET was recently proposed as a tool for detection of CSF clearance alterations in Alzheimer's disease. The current study seeks to investigate the magnitude of C-PiB PET signal in the lateral ventricles of an independent group of Alzheimer's and mild cognitive impairment subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223834DOI Listing
March 2019
1 Read

State of the Art: Evaluating the Role of Theranostics in G3 Neuroendocrine Neoplasms.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

Stanford University Medical Center, United States.

The diagnosis and subsequent therapy of neuroendocrine neoplasms (NENs) have long-relied on somatostatin receptor (SSTR) expression. The field of theranostics now uses newer SSTR based Positron Emission Tomography (SSTR-PET) imaging with Ga-DOTA0-Tyr3-Octreotate (Ga-DOTATATE) or Ga-DOTA0-Tyr3-Octreotide (Ga-DOTATOC), as a prerequisite for the administration of peptide receptor radionuclide therapy (PRRT). In the US, Lu-Dotatate, a form of PRRT, gained FDA approval in 2018 for use in gastroenteropancreatic NENs and was based on prolonged progression-free survival (PFS) vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.217851DOI Listing
March 2019
1 Read

Effect of external cooling on Lu-177 PSMA uptake for parotid glands.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

University of Health Sciences, Istanbul Research and Training Hospital, Nuclear Medicine Department, Turkey.

Metastatic castration-resistant prostate cancer (mCRPC) patients have been started to treat with prostate-specific membrane antigen (PSMA) targeted radioligand therapy (PRLT), especially with Lu-177 PSMA-617 in recent years. But, side effects of PRLT against salivary glands, limits the treatment safety. Current study aims to show the effect of external cooling with icepacks on Lu-177 PSMA-617 uptake in parotid glands (PGs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.226449DOI Listing
March 2019
10 Reads

Side effects of CXC-chemokine receptor 4 - directed Endoradiotherapy with Pentixather prior to Hematopoietic Stem Cell Transplantation.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

Department of Nuclear Medicine, University Hospital Würzburg, Germany.

The chemokine receptor CXCR4 is a transmembrane receptor involved in survival, proliferation and dissemination of different cancers, including hematopoietic malignancies. Relapsed/refractory hematopoietic cancers are frequently resistant to conventional therapy and novel highly active strategies are urgently needed. CXCR4-directed endoradiotherapy constitutes a highly promising targeted therapeutic concept. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223420DOI Listing
March 2019
2 Reads

Development of novel FAP-targeted radiotracers with improved tumor retention.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

University Hospital Heidelbergn, Germany.

Cancer associated fibroblasts constitute a vital subpopulation of the tumor stroma and are present in more than 90% of epithelial carcinomas. The overexpression of the serine protease fibroblast activation protein (FAP) allows a selective targeting of a variety of tumors by inhibitor-based radiopharmaceuticals (FAPIs). Of these compounds, FAPI-04 has been recently introduced as theranostic radiotracer and demonstrated high uptake into different FAP-positive tumors in cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.224469DOI Listing
March 2019
1 Read

Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence - a narrative review of literature.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

Radiology and Nuclear Medicine Department, Radboud University Medical Center, Netherlands.

Gallium-68 and Fluor-18 labeled prostate specific membrane antigen (PSMA) molecules have created new opportunities for the unmet diagnostic needs in prostate cancer. The purpose of this study is to give an overview of the studies that have examined the role of PSMA PET scan in treatment planning in prostate cancer patients with biochemical recurrence. Medline, Embase, Web of Science, Google Scholar, and Cochrane Central were searched for relevant articles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222885DOI Listing
March 2019
1 Read

Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

Zentralklink Bad Berka, Germany.

The aim of this study was to assess the safety, tolerability and effects on renal function as well as therapeutic efficacy of prostate-specific membrane antigen (PSMA) targeted radioligand therapy (PRLT) using lutetium-177 (Lu) labeled PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) and a single functioning kidney before PRLT. Sixteen patients (age 53-78 y, mean age 64.7 ± 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223149DOI Listing
March 2019
2 Reads

Ga-DOTA-E[c(RGDfK)] Positron Emission Tomography Imaging of SHARPIN-Regulated Integrin Activity in Mice.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

Turku PET Centre, Finland.

Shank-associated RH domain-interacting protein (SHARPIN, alias SIPL1) is a cytosolic protein that plays a key role in activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and regulation of inflammation. Furthermore, SHARPIN controls integrin-dependent cell adhesion and migration in several normal and malignant cell types, and loss of SHARPIN correlates with increased integrin activity in mice. Arginyl-glycyl-aspartic acid (RGD), a cell adhesion tripeptide motif, is an integrin recognition sequence that facilitates positron emission tomography (PET) imaging of integrin upregulation during tumor angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222026DOI Listing

Cu-intraperitoneal radioimmunotherapy: a novel approach for adjuvant treatment in a clinically relevant preclinical model of pancreatic cancer.

J Nucl Med 2019 Mar 8. Epub 2019 Mar 8.

National Institute of Radiological Sciences, QST, Japan.

Pancreatic cancer (PC) has a very poor prognosis. Surgery is the primary treatment for patients with resectable PC; however, local recurrence, hepatic metastasis, and peritoneal dissemination often occur even after extensive surgery. Adjuvant chemotherapy, typically with gemcitabine, has been used clinically, but with only a modest survival benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.225045DOI Listing
March 2019
2 Reads